

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/522,415
Filing Date	July 31, 2003
First Named Inventor	Vivian I. TEICHBERG
Group Art Unit	1615
Examiner Name	unknown
Attorney Docket Number	29147

Sheet	2	Of	3
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TG	2	Matthews et al. "Enzymatic Degradation Protects Neurons From Glutamate Excitotoxicity", Journal of Neurochemistry, 75(3): 1045-1052, 2000.	
	3	Jiang et al. "Glutamate Is A Principal Mediator of HIV-1-Infected Immune Competent Human Macrophage Neurotoxicity", Society for Neuroscience Abstracts, 26(1-2), Abstract No. 136.17, 30th Annual Meeting of the Society of Neuroscience, New Orleans, USA, 2000.	
	4	Di Giorgio et al. "Gabaergic Systems in Brain Regions of Glutamate-Lesioned Rats", Italien Journal of Biochemistry, 34(1): 19-28, 1985. P.19, Line 15.	
	5	Engelhardt et al. "The Diagnostic Value of Enzyme Determination in Cerebrospinal Fluid", Medizinische Klinik, München, 71(17): 699-702, 1976. P.701.	
	6	Andrae et al. "Pyruvate and Related α -Ketoacids Protect Mammalian Cells in Culture Against Hydrogen Peroxide-Induced Cytotoxicity", Toxicology Letters, 28: 93-98, 1985.	
	7	Avramis et al. "A Randomized Comparison of Native Escherichia Coli Asparaginase and Polyethelyne Glycol Conjugated Asparaginase for Treatment of Children With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia: A Children's Cancer Group Study", Blood, 99(6): 1986-1994, 2002.	
	8	Cavallini et al. "The Protective Action of Pyruvate on Recovery of Ischemic Rat Heart: Comparison With Other Oxidizable Substrates", Journal of Molecular Cell Cardiology, 22: 143-154, 1990.	
	9	Desagher et al. "Pyruvate Protects Neurons Against Hydrogen Peroxide-Induced Toxicity", The Journal of Neuroscience, 17(23): 9060-9067, 1997.	
	10	Gramsbergen et al. "Pyruvate Protects Against 3-Nitropropionic Acid Neurotoxicity in Corticostriatal Slice Cultures", Neuropharmacology, 11(21): 2743-2747, 2000.	
	11	Hosoya et al. "Blood-Brain Barrier Produces Significant Efflux of L-Aspartic Acid But Not D-Aspartic Acid: In Vivo Evidence Using the Brain Efflux Index Method", Journal of Neurochemistry, 73: 1206-1211, 1999.	
	12	Lee et al. "Protection by Pyruvate Against Transient Forebrain Ischemia in Rats", The Journal of Neuroscience, 21(RC171): 1-6, 2001.	
	13	Liu et al. "P-Glycoprotein Regulated Transport of Glutamate at Blood-Brain Barrier", Acta Pharmacol Sin, 22(2): 111-116, 2001.	
	14	Matsumoto et al. "Role of Pyruvate in Ischemia-Like Conditions on Cultured Neurons", Neurological Research, 16: 460-464, 1994.	
	15	Matthews et al. "Glutamate-Pyruvate Transaminase Protects Against Glutamate Toxicity in Hippocampal Slices", Brain Research, 978: 59-64, 2003.	
	16	Matthews et al. "Enzymatic Degradation Protects Neurons From Glutamate Excitotoxicity", Journal of Neurochemistry, 75: 1045-1052, 2000.	
	17	Maus et al. "Pyruvate and Lactate Protect Striatal Neurons Against N-Methyl-D-Aspartate-Induced Neurotoxicity", European Journal of Neuroscience, 11: 3215-3224, 1999.	
	18	Mongan et al. "Pyruvate Improves Cerebral Metabolism During Hemorrhagic Shock", AJP - Heart and Circulatory Physiology, 281: 854-864, 2001.	
	19	Mongan et al. "Intravenous Pyruvate Prolongs Survival During Hemorrhagic Shock in Swine", AJP - Heart and Circulatory Physiology, 277(46): H2253-H2263, 1999.	
TG	20	O'Kane et al. "Na ⁺ -Independent Glutamate Transporters (EAAT1, EAAT2, and EAAT3) of the Blood-Brain Barrier", The Journal of Biological Chemistry, 274(45): 31891-31895, 1999.	



TG	21	Ruiz et al. "Protection by Pyruvate and Malate Against Glutamate-Mediated Neurotoxicity", NeuroReport, 9: 1277-1282, 1998.	
TG	22	Ryu et al. "Neuroprotective Effects of Pyruvate in the Quinolinic Acid Rat Model of Huntington's Disease", Experimental Neurology, 183: 700-704, 2003.	
TG	23	Steele "Blood-Brain Barrier Transport of the α -Keto Acid Analogs of Amino Acids", Federation Proceedings, 45(7): 2060-2064, 1986	
TG	24	Stover et al. "Neurotransmitters in Cerebrospinal Fluid Reflect Pathological Activity", European Journal of Clinical Investigation, 27: 1038-1043, 1997.	
TG	25	Wolff et al. "The Effectiveness of Benzoate in the Management of Seizures in Nonketotic Hyperglycinemia", AJDC, 140: 596-602, 1986.	

Signature	/Tiffany Gough/	Considered	05/18/2006
-----------	-----------------	------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.